Development of (225)Ac Production from Low Isotopic Dilution (229)Th

[Image: see text] The promise of (225)Ac targeted alpha therapies has been on the horizon for the last two decades. TerraPower Isotopes are uniquely suited to produce clinically relevant quantities of (225)Ac through the decay of (229)Th. Herein, a rapid processing scheme to isolate radionuclidic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Camacaro, Jose F., Dunckley, Christopher P., Harman, S. Elizabeth, Fitzgerald, Hilary A., Lakes, Andrew L., Liao, Zuolei, Ludwig, Russell C., McBride, Katie M., Yalcintas Bethune, Ezgi, Younes, Ali, Chatterjee, Sayandev, Lilley, Laura M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601055/
https://www.ncbi.nlm.nih.gov/pubmed/37901510
http://dx.doi.org/10.1021/acsomega.3c01769
Descripción
Sumario:[Image: see text] The promise of (225)Ac targeted alpha therapies has been on the horizon for the last two decades. TerraPower Isotopes are uniquely suited to produce clinically relevant quantities of (225)Ac through the decay of (229)Th. Herein, a rapid processing scheme to isolate radionuclidic and radioisotopically pure (225)Ac in good yield (98%) produced from (229)Th that contains significant quantities of (228)Th activity is described. The characterization of each step of the process is presented along with the detailed characterization of the resulting (225)Ac isotopic starting material that will support the cancer research and development efforts.

Ejemplares similares